Shennon Biotechnologies
CA - San FranciscoBiotechnology
Focus: Shennon Biotechnologies is a early-stage biotech company developing a proprietary single-cell platform designed to create more effective immunotherapies in oncology and neurology. The company operates as a pre-revenue biotech with minimal public market presence.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Open Jobs
4+2 this month
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Should You Work at Shennon Biotechnologies?
AI assessmentShennon is a high-risk, high-reward early-stage play suitable only for risk-tolerant scientists seeking equity upside and platform-building experience, not stability or near-term career momentum.
Why Work Here
- Platform-driven innovation — proprietary single-cell technology offers rare opportunity to build foundational IP early in company lifecycle
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Shennon Biotechnologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.